Global Information
회사소개 | 문의

척수신경 자극기 : 파이프라인 리뷰

Spinal Cord Stimulators - Medical Devices Pipeline Assessment, 2018

리서치사 GlobalData
발행일 2018년 06월 상품 코드 345363
페이지 정보 영문 113 Pages
가격
US $ 4,000 ₩ 4,488,800 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 8,000 ₩ 8,977,600 PDF by E-mail (Site License) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 12,000 ₩ 13,466,400 PDF by E-mail (Global License) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


척수신경 자극기 : 파이프라인 리뷰 Spinal Cord Stimulators - Medical Devices Pipeline Assessment, 2018
발행일: 2018년 06월 페이지 정보 : 영문 113 Pages

한글목차

세계 각국 기업 및 의료기관 등에서 개발하고 있는 척수신경 자극기(Spinal Cord Stimulators) 파이프라인 제품 정보에 대해 분석했으며, 임상시험과 제품 개발 진행 상황, 단계별·부문별·국가(지역)별 동향, 기업과 제품 상세 정보, 최근의 제품 개발 및 업계 동향 등의 정보를 전해드립니다.

제1장 목차

제2장 서론

  • 척수신경 자극기 개요

제3장 개발중인 제품

  • 척수신경 자극기 : 개발 단계별 파이프라인 제품
  • 척수신경 자극기 : 국가(지역)별 파이프라인 제품
  • 척수신경 자극기 : 규제별 파이프라인 제품
  • 척수신경 자극기 : 인증 시기별(추정) 파이프라인 제품
  • 척수신경 자극기 : 현재 진행중인 임상시험

제4장 척수신경 자극기 : 개발중인 파이프라인 제품 - 기업별

  • 척수신경 자극기 기업 : 개발 단계별 파이프라인 제품
  • 척수신경 자극기 : 개발 단계별 파이프라인 제품

제5장 척수신경 자극기 기업과 제품 개요

  • Boston Scientific Corporation
  • Direct Spinal Therapeutics, Inc.
  • Duke University
  • Imperial College London
  • Meagan Medical Inc.
  • Medtrode Inc.
  • Medtronic plc
  • MicroTransponder Inc.
  • NeuroRecovery Technologies Inc.
  • Nuvectra Corporation
  • Saluda Medical Pty Ltd
  • St. Jude Medical, Inc.
  • Stimwave Technologies, Inc.

제6장 척수신경 자극기 : 최근 동향

제7장 부록

LSH 15.11.30

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

영문목차

GlobalData's Medical Devices sector report, "Spinal Cord Stimulators - Medical Devices Pipeline Assessment, 2018" provides an overview of Spinal Cord Stimulators currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Spinal Cord Stimulators pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Spinal Cord Stimulators under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Spinal Cord Stimulators and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Spinal Cord Stimulators under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 5
  • 1.2 List of Figures 7

2 Introduction 8

  • 2.1 Spinal Cord Stimulators Overview 8

3 Products under Development 9

  • 3.1 Spinal Cord Stimulators - Pipeline Products by Stage of Development 9
  • 3.2 Spinal Cord Stimulators - Pipeline Products by Territory 10
  • 3.3 Spinal Cord Stimulators - Pipeline Products by Regulatory Path 11
  • 3.4 Spinal Cord Stimulators - Pipeline Products by Estimated Approval Date 12
  • 3.5 Spinal Cord Stimulators - Ongoing Clinical Trials 13

4 Spinal Cord Stimulators - Pipeline Products under Development by Companies 14

  • 4.1 Spinal Cord Stimulators Companies - Pipeline Products by Stage of Development 14
  • 4.2 Spinal Cord Stimulators - Pipeline Products by Stage of Development 15

5 Spinal Cord Stimulators Companies and Product Overview 16

  • 5.1 Boston Scientific Corp Company Overview 16
    • 5.1.1 Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16
  • 5.2 Cerevast Therapeutics Inc Company Overview 17
    • 5.2.1 Cerevast Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 17
  • 5.3 Direct Spinal Therapeutics, Inc. Company Overview 18
    • 5.3.1 Direct Spinal Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
  • 5.4 Duke University Company Overview 19
    • 5.4.1 Duke University Pipeline Products & Ongoing Clinical Trials Overview 19
  • 5.5 G-Therapeutics SA Company Overview 20
    • 5.5.1 G-Therapeutics SA Pipeline Products & Ongoing Clinical Trials Overview 20
  • 5.6 Imperial College London Company Overview 23
    • 5.6.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 23
  • 5.7 Mayo Clinic Company Overview 24
    • 5.7.1 Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.8 Meagan Medical Inc. Company Overview 25
    • 5.8.1 Meagan Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.9 Medtronic plc Company Overview 28
    • 5.9.1 Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 28
  • 5.10 MicroTransponder Inc Company Overview 30
    • 5.10.1 MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.11 Nalu Medical Inc Company Overview 31
    • 5.11.1 Nalu Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.12 NeuroRecovery Technologies Inc. Company Overview 32
    • 5.12.1 NeuroRecovery Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.13 Nevro Corp Company Overview 34
    • 5.13.1 Nevro Corp Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.14 Nuvectra Corporation Company Overview 42
    • 5.14.1 Nuvectra Corporation Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.15 PathMaker Neurosystems Inc Company Overview 43
    • 5.15.1 PathMaker Neurosystems Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.16 Saluda Medical Pty Ltd Company Overview 46
    • 5.16.1 Saluda Medical Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.17 Soterix Medical Inc Company Overview 49
    • 5.17.1 Soterix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.18 St. Jude Medical LLC Company Overview 55
    • 5.18.1 St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 55
  • 5.19 University of California Los Angeles Company Overview 61
    • 5.19.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 61
  • 5.20 WISE s.r.l. Company Overview 62
    • 5.20.1 WISE s.r.l. Pipeline Products & Ongoing Clinical Trials Overview 62

6 Spinal Cord Stimulators- Recent Developments 63

  • 6.1 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy 63
  • 6.2 May 07, 2018: Stimwave Appoints Dr. Andrea Trescot As Chief Medical Officer 63
  • 6.3 May 07, 2018: Nevro Reports First Quarter 2018 Financial Results 64
  • 6.4 May 02, 2018: Nuvectra Reports First Quarter 2018 Financial Results 65
  • 6.5 Apr 25, 2018: Boston Scientific Reports Financial Results For First Quarter 2018 66
  • 6.6 Apr 05, 2018: Dr. Laura Mauri to Join Medtronic as Vice President, Global Clinical Research & Analytics 68
  • 6.7 Mar 22, 2018: Full-Body MRI Conditional Labeling Now Available in United States for Nevro Senza Spinal Cord Stimulation System 68
  • 6.8 Mar 06, 2018: Nuvectra Reports Fourth Quarter and Full Year 2017 Financial Results 69
  • 6.9 Feb 28, 2018: Agilent and Imperial College London Announce Collaboration Agreement 70
  • 6.10 Feb 22, 2018: Nevro Reports Fourth Quarter and Full Year 2017 Financial Results and Provides 2018 Outlook 71
  • 6.11 Feb 07, 2018: PathMaker Neurosystems Awarded Nearly $5 Million NIH Cooperative Agreement to Develop MyoRegulator for the Non-Invasive Treatment of Spasticity 72
  • 6.12 Feb 01, 2018: Boston Scientific Announces Results for Fourth Quarter and Full Year 2017 72
  • 6.13 Jan 31, 2018: PathMaker Neurosystems Announces the Addition of Professor Ole Isacson of Harvard Medical School to its Scientific Advisory Board 74
  • 6.14 Jan 30, 2018: Alex Gu Named Senior Vice President and President of Medtronic's Greater China Region 75
  • 6.15 Jan 12, 2018: Nevro to Highlight Body of Clinical Evidence Supporting Expanded Use and Potential New Indications of Company's Senza Spinal Cord Stimulation Systems Delivering HF10 Therapy at NANS Annual Meeting 76
  • 6.16 Jan 11, 2018: Boston Scientific Receives U.S. FDA Approval for Spectra WaveWriter Spinal Cord Stimulator System 76
  • 6.17 Jan 09, 2018: Medtronic Enrolls First Patient In Pain Study to Assess Optimized Spinal Cord Stimulation Programming 77
  • 6.18 Jan 09, 2018: Boston Scientific Announces Preliminary Unaudited Sales For The Fourth Quarter And Full Year Ended December 31, 2017 78
  • 6.19 Jan 08, 2018: Nevro Receives FDA Approval for Senza II Spinal Cord Stimulation System Delivering HF10 Therapy 78
  • 6.20 Jan 08, 2018: Nuvectra Announces Preliminary Unaudited Fourth Quarter and Full Year 2017 Revenue 79
  • 6.21 Jan 08, 2018: Nevro Announces Preliminary Unaudited Fourth Quarter and Fiscal Year 2017 Revenue 79
  • 6.22 Dec 19, 2017: Bob White Named Executive Vice President and President of Medtronic's Minimally Invasive Therapies Group; Chris Lee to Assume Leadership of Medtronic's Asia Pacific Region 80
  • 6.23 Dec 14, 2017: Stimwave Appoints Industry Veteran Jim Surek as Chief Commercialization Officer and Adds Konstantin Slavin, M.D. to Medical Advisory Board 81
  • 6.24 Dec 13, 2017: Nuvectra Achieves 1,000th Algovita SCS System Implantation in U.S. 82
  • 6.25 Nov 30, 2017: Nevro Receives CE Mark for Senza II Spinal Cord Stimulation System Delivering HF10 Therapy 82
  • 6.26 Nov 21, 2017: Medtronic Reports Second Quarter Financial Results 83
  • 6.27 Nov 15, 2017: Nevro Receives CE Mark for Full-Body MRI Conditional Labeling with the Senza Spinal Cord Stimulation System 86
  • 6.28 Nov 08, 2017: Medtronic Announces Preliminary Second Quarter Revenue 86
  • 6.29 Nov 06, 2017: Medtronic Receives CE Mark for the World's Smallest Fully Implantable Spinal Cord Stimulator and Announces European Launch of the Intellis Platform 87
  • 6.30 Nov 06, 2017: Nevro Reports Third Quarter 2017 Financial Results 89
  • 6.31 Nov 02, 2017: Medtronic Releases Fiscal Year 2017 Integrated Performance Report 89
  • 6.32 Nov 01, 2017: Nuvectra Reports Third Quarter 2017 Financial Results 90
  • 6.33 Oct 26, 2017: Boston Scientific Announces Results For Third Quarter 2017 91
  • 6.34 Oct 16, 2017: Patients Battling Complex Regional Pain Syndrome Find a Host of New Benefits in Abbott's Proclaim DRG System 92
  • 6.35 Oct 06, 2017: Medtronic Provides Update on Impact from Hurricane Maria 93
  • 6.36 Oct 04, 2017: Boston Scientific Appoints Desiree Ralls-Morrison General Counsel and Corporate Secretary 94
  • 6.37 Oct 02, 2017: Stimwave Expands Commercialization Efforts For Neuromodulation Device Freedom Spinal Cord Stimulation (SCS) System 95
  • 6.38 Sep 18, 2017: Medtronic Announces FDA Approval and U.S. Launch of Next Generation Spinal Cord Stimulator for Chronic Pain Management 96
  • 6.39 Sep 11, 2017: First Spinal Cord Stimulator Implant Placed in Northern California by Dr. Goldthwaite Brings Pain Relief and Reduces Opioid Use for Local Injured Veteran 97
  • 6.40 Aug 22, 2017: Medtronic Reports First Quarter Financial Results 98
  • 6.41 Aug 08, 2017: Nuvectra Reports Second Quarter 2017 Financial Results 100
  • 6.42 Aug 07, 2017: Nevro Reports Second Quarter 2017 Financial Results 101
  • 6.43 Jul 27, 2017: Boston Scientific Announces Results for Second Quarter 2017 101
  • 6.44 Jul 05, 2017: Nevro Announces Preliminary Unaudited Second Quarter 2017 Revenue and Business Update 103
  • 6.45 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 104
  • 6.46 Jun 21, 2017: Nuvectra Files Regulatory Submission with FDA for Algovita MRI-Conditional Approval 106
  • 6.47 May 25, 2017: Medtronic Reports Fourth Quarter and Fiscal Year 2017 Financial Results 106
  • 6.48 May 24, 2017: Stimwave Appoints Pat Tompkins as Executive Vice President of Sales 109

7 Appendix 110

  • 7.1 Methodology 110
  • 7.2 About GlobalData 113
  • 7.3 Contact Us 113
  • 7.4 Disclaimer 113

List of Tables

1.1 List of Tables

  • Table 1: Spinal Cord Stimulators - Pipeline Products by Stage of Development 9
  • Table 2: Spinal Cord Stimulators - Pipeline Products by Territory 10
  • Table 3: Spinal Cord Stimulators - Pipeline Products by Regulatory Path 11
  • Table 4: Spinal Cord Stimulators - Pipeline Products by Estimated Approval Date 12
  • Table 5: Spinal Cord Stimulators - Ongoing Clinical Trials 13
  • Table 6: Spinal Cord Stimulators Companies - Pipeline Products by Stage of Development 14
  • Table 7: Spinal Cord Stimulators - Pipeline Products by Stage of Development 15
  • Table 8: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview 16
  • Table 9: Next Generation SCS System - Product Status 16
  • Table 10: Next Generation SCS System - Product Description 16
  • Table 11: Cerevast Therapeutics Inc Pipeline Products & Ongoing Clinical Trials Overview 17
  • Table 12: Transdermal Electrical Neurostimulation Device - Product Status 17
  • Table 13: Transdermal Electrical Neurostimulation Device - Product Description 17
  • Table 14: Direct Spinal Therapeutics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 18
  • Table 15: Iowa-Patch System - Product Status 18
  • Table 16: Iowa-Patch System - Product Description 18
  • Table 17: Duke University Pipeline Products & Ongoing Clinical Trials Overview 19
  • Table 18: Spinal Cord Stimulator - Product Status 19
  • Table 19: Spinal Cord Stimulator - Product Description 19
  • Table 20: G-Therapeutics SA Pipeline Products & Ongoing Clinical Trials Overview 20
  • Table 21: Implantable Neuro-Stimulation System - Product Status 20
  • Table 22: Implantable Neuro-Stimulation System - Product Description 20
  • Table 23: G-Therapeutics SA - Ongoing Clinical Trials Overview 21
  • Table 24: Implantable Neuro-Stimulation System - Feasibility Study: fMRI Evaluation of Auricular PENFS for Fibromyalgia 22
  • Table 25: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 23
  • Table 26: Wireless Intraspinal Microstimulation System - Product Status 23
  • Table 27: Wireless Intraspinal Microstimulation System - Product Description 23
  • Table 28: Mayo Clinic Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 29: Spinal Cord Electrical Stimulator - Product Status 24
  • Table 30: Spinal Cord Electrical Stimulator - Product Description 24
  • Table 31: Meagan Medical Inc. Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 32: DISCSS IFC System - Product Status 25
  • Table 33: DISCSS IFC System - Product Description 25
  • Table 34: Meagan Medical Inc. - Ongoing Clinical Trials Overview 26
  • Table 35: DISCSS IFC System - Pilot Study to Examine the Feasibility of the DISCSS 27
  • Table 36: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview 28
  • Table 37: MRI Surgical Lead - Product Status 28
  • Table 38: MRI Surgical Lead - Product Description 28
  • Table 39: PrimeADVANCED - Heart Failure - Product Status 29
  • Table 40: PrimeADVANCED - Heart Failure - Product Description 29
  • Table 41: MicroTransponder Inc Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 42: SAINT System - Chronic Pain - Product Status 30
  • Table 43: SAINT System - Chronic Pain - Product Description 30
  • Table 44: Nalu Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 45: Microstimulator - Spinal Cord - Product Status 31
  • Table 46: Microstimulator - Spinal Cord - Product Description 31
  • Table 47: NeuroRecovery Technologies Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 48: External Spinal Cord Neuromodulation System - Product Status 32
  • Table 49: External Spinal Cord Neuromodulation System - Product Description 32
  • Table 50: Implantable Spinal Cord Stimulation Device - Product Status 33
  • Table 51: Implantable Spinal Cord Stimulation Device - Product Description 33
  • Table 52: Nevro Corp Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 53: SENZA-CAP - Chronic Abdominal Pain - Product Status 34
  • Table 54: SENZA-CAP - Chronic Abdominal Pain - Product Description 34
  • Table 55: SENZA-CPSP - Post Surgical Pain - Product Status 35
  • Table 56: SENZA-CPSP - Post Surgical Pain - Product Description 35
  • Table 57: SENZA-PDN - Painful Diabetic Neuropathy - Product Status 35
  • Table 58: SENZA-PDN - Painful Diabetic Neuropathy - Product Description 35
  • Table 59: SENZA-PPN - Peripheral Polyneuropathy - Product Status 36
  • Table 60: SENZA-PPN - Peripheral Polyneuropathy - Product Description 36
  • Table 61: SENZA-ULN - Neck Pain - Product Status 36
  • Table 62: SENZA-ULN - Neck Pain - Product Description 36
  • Table 63: SENZA-ULN - Upper Limb Pain - Product Status 37
  • Table 64: SENZA-ULN - Upper Limb Pain - Product Description 37
  • Table 65: Nevro Corp - Ongoing Clinical Trials Overview 38
  • Table 66: SENZA-ULN - Neck Pain - Multi-center, Prospective, Clinical Trial of the Senza Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Upper Limb and Neck Pain 39
  • Table 67: SENZA-ULN - Upper Limb Pain - Multi-center, Prospective, Clinical Trial of the Senza Spinal Cord Stimulation (SCS) System in the Treatment of Chronic Upper Limb and Neck Pain 40
  • Table 68: SENZA-PDN - Painful Diabetic Neuropathy - A Post-market, Multicenter, Prospective, Randomized Clinical Trial Comparing 10 kHz Spinal Cord Stimulation (HF10 Therapy) Combined with Conventional Medical Management to Conventional Medical Management Alone in the Treatment of Chronic, Intractable, Neuropathic Limb Pain 41
  • Table 69: Nuvectra Corporation Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 70: Algovita SCS System - Full Body MRI - Product Status 42
  • Table 71: Algovita SCS System - Full Body MRI - Product Description 42
  • Table 72: PathMaker Neurosystems Inc Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 73: MyoRegulator PM-2200 - Product Status 43
  • Table 74: MyoRegulator PM-2200 - Product Description 43
  • Table 75: PathMaker Neurosystems Inc - Ongoing Clinical Trials Overview 44
  • Table 76: MyoRegulator PM-2200 - First European Clinical Trial of MyoRegulator to Treat Muscle Contraction 45
  • Table 77: MyoRegulator PM-2200 - The Effect of Treatment with the Pathmaker Myoregulator Neuromodulation System Incorporating Trans-spinal Direct Current Stimulation (tsDCS) in Patients with Severe Hand Spasticity after Stroke 45
  • Table 78: Saluda Medical Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 79: Evoke Spinal Cord Stimulator System - Product Status 46
  • Table 80: Evoke Spinal Cord Stimulator System - Product Description 46
  • Table 81: Saluda Medical Pty Ltd - Ongoing Clinical Trials Overview 47
  • Table 82: Evoke Spinal Cord Stimulator System - A Prospective, Multicenter, Randomized Double-blind Study Examining the Safety and Efficacy of Using the Evoke Spinal Cord Stimulator (SCS) System with Feedback to Treat Patients with Chronic Pain of the Trunk and/or Limbs 48
  • Table 83: Soterix Medical Inc Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 84: 1×1 tDCS Device - Product Status 49
  • Table 85: 1×1 tDCS Device - Product Description 49
  • Table 86: Soterix Medical Inc - Ongoing Clinical Trials Overview 50
  • Table 87: 1×1 tDCS Device - A Pilot Study of the Tolerability and Efficacy of Transcranial Direct Current Stimulation (tDCS) in Children and Adolescents with Epilepsy and Comorbid Depression 51
  • Table 88: 1×1 tDCS Device - Accelerating Motor Learning in Pediatrics 51
  • Table 89: 1×1 tDCS Device - Boston-harvard Burn Injury Model System: Cortical Modulation with Transcranial Direct Current Stimulation (tDCS) for Neuropathic Symptoms Following Burn Injury 51
  • Table 90: 1×1 tDCS Device - Effects of Transcranial Direct Current Stimulation (tDCS) in Spoken and Written Production in Primary Progressive Aphasia (PPA) 52
  • Table 91: 1×1 tDCS Device - Home-Administered Transcranial Direct Current Stimulation (tDCS) Treatment for Depression 52
  • Table 92: 1×1 tDCS Device - Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS) 52
  • Table 93: 1×1 tDCS Device - Promoting Adaptive Neuroplasticity in Mild Cognitive Impairment 53
  • Table 94: 1×1 tDCS Device - Stimulation for Perinatal Stroke Optimizing Recovery Trajectories 53
  • Table 95: 1×1 tDCS Device - Transcranial Direct Current Stimulation to Enhance Cognition in Mild Cognitive Impairment 53
  • Table 96: 1×1 tDCS Device - Using tDCS in Speech-based Stroke Rehabilitation 54
  • Table 97: St. Jude Medical LLC Pipeline Products & Ongoing Clinical Trials Overview 55
  • Table 98: Next Generation Implantable SCS System - Primary Cell - Product Status 55
  • Table 99: Next Generation Implantable SCS System - Primary Cell - Product Description 55
  • Table 100: Next Generation Implantable SCS System - Rechargeable - Product Status 56
  • Table 101: Next Generation Implantable SCS System - Rechargeable - Product Description 56
  • Table 102: Proclaim Rechargeable Model - Product Status 56
  • Table 103: Proclaim Rechargeable Model - Product Description 56
  • Table 104: Proclaim Upgrade HC - Product Status 57
  • Table 105: Proclaim Upgrade HC - Product Description 57
  • Table 106: Proclaim Upgrade LC - Product Status 57
  • Table 107: Proclaim Upgrade LC - Product Description 58
  • Table 108: Prodigy SCS System - Product Status 58
  • Table 109: Prodigy SCS System - Product Description 58
  • Table 110: St. Jude Medical LLC - Ongoing Clinical Trials Overview 59
  • Table 111: Prodigy SCS System - Multi-center Prospective Study Determining the Sustainability of Pain Relief and Psychosocial and Functional Responses when Utilizing a Multiple Waveform Enabled Neurostimulator 60
  • Table 112: University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 61
  • Table 113: 32-Electrode Neurostimulator - Product Status 61
  • Table 114: 32-Electrode Neurostimulator - Product Description 61
  • Table 115: WISE s.r.l. Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 116: Foldable SCS Paddle Leads - Product Status 62
  • Table 117: Foldable SCS Paddle Leads - Product Description 62
  • Table 118: Glossary 112

List of Figures

1.2 List of Figures

  • Figure 1: Spinal Cord Stimulators - Pipeline Products by Stage of Development 9
  • Figure 2: Spinal Cord Stimulators - Pipeline Products by Territory 10
  • Figure 3: Spinal Cord Stimulators - Pipeline Products by Regulatory Path 11
  • Figure 4: Spinal Cord Stimulators - Pipeline Products by Estimated Approval Date 12
  • Figure 5: Spinal Cord Stimulators - Ongoing Clinical Trials 13
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research